Valvular & structural heart diseaseRandomised controlled trial
Outcomes of SAPIEN 3 Transcatheter Aortic Valve Replacement Compared With Surgical Valve Replacement in Intermediate-Risk Patients
- Propensity-matched comparison of the PARTNER 2 S3 single-arm study and the PARTNER 2A randomised trial
- propensity-score matched
Authors' conclusion
In this propensity-matched analysis of intermediate-risk patients, 5-year rates of death and disabling stroke were similar between S3 TAVR and SAVR.
Study context
- Population
- Intermediate-risk patients with severe AS783 matched pairs
- Comparison
- S3 transcatheter aortic valve replacement (TAVR) vs surgical aortic valve replacement (SAVR)
- Primary endpoint
- Composite of:
- All-cause death
- Disabling stroke
- Follow-up
- 5 years
Primary result
As reported in the abstract
Hazard ratio
0.87
95% CI 0.74–1.03
P = 0.10
By group
S3 TAVR vs SAVR
HR 0.87 (95% CI 0.74–1.03); P = 0.10
Further findings
SVD-related stage 2 and 3 hemodynamic valve deterioration or bioprosthetic valve failure
- No differences between S3 TAVR and SAVR
Safety
Mild or greater paravalvular regurgitation
- More common after S3 TAVR
Original publication
Outcomes of SAPIEN 3 Transcatheter Aortic Valve Replacement Compared With Surgical Valve Replacement in Intermediate-Risk Patients. J Am Coll Cardiol. Published 11 July 2023. doi:10.1016/j.jacc.2023.04.049
Summarised from the published abstract; every number is checked against it